Scholars Central

OpinionPublished 30 Jun 2025

CRISPR-Cas Gene Editing in Cancer: A Transformative Frontier in Clinical Oncology

Authors: Michael R. Ellington

Reports in Cancer and Treatment

Volume 9 · Issue 2 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

CRISPR-Cas gene editing has emerged as one of the most revolutionary technologies in modern biomedical science, offering unprecedented precision in manipulating the human genome. In oncology, CRISPR has reshaped approaches to cancer modeling, diagnosis, and therapy by enabling targeted modification of oncogenes, tumor suppressor genes, and immune pathways. This opinion article explores the evolving role of CRISPR in clinical oncology, highlighting its therapeutic promise, translational barriers, ethical considerations, and future prospects. While early clinical trials show encouraging safety and efficacy signals, significant challenges—including off-target effects, delivery limitations, tumor heterogeneity, and regulatory constraints—continue to restrict widespread clinical adoption. The article argues that CRISPR is not a standalone cure but a foundational enabling platform that, when integrated with immunotherapy and precision medicine, could redefine cancer treatment paradigms.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Reports in Cancer and Treatment.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalReports in Cancer and Treatment
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Michael R. Ellington”